Dexcom | Jotup

DexCom Comments on SVB Relationship

Retrieved on:

星期一, 三月 13, 2023

Diabetes, Pharmaceutical, Health, Medical Devices, DXCM, Dexcom, SVB, Silicon, CNBC, Silicon Valley Bank, 3D printing, Security (finance), Bank

DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article:

Key Points:

DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article:
“Dexcom does not have material exposure to the developments at Silicon Valley Bank, including with respect to the company’s cash deposits.
Although the company has worked successfully with SVB for many years, Dexcom does not have any exclusive banking relationship with SVB.
As noted in Dexcom’s recent filing on form 10-K, the company currently retains approximately $2.5 billion in cash, cash equivalents, and short-term marketable securities.
Approximately $2.7 million of this amount is held at SVB.”

DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results

Retrieved on:

星期四, 三月 9, 2023

"Notably, operating loss in the fourth quarter declined by 58% to $9 million compared to $21.7 million in the fourth quarter of 2021 and non-GAAP operating loss in the fourth quarter declined by 60% to $6 million compared to $15 million in the fourth quarter of 2021.

Key Points:

"Notably, operating loss in the fourth quarter declined by 58% to $9 million compared to $21.7 million in the fourth quarter of 2021 and non-GAAP operating loss in the fourth quarter declined by 60% to $6 million compared to $15 million in the fourth quarter of 2021.
Gross profit as a percentage of revenues increased to 40.1% in the fourth quarter of 2022, from 9.1% in the fourth quarter of 2021, and 27.3% in the third quarter of 2022.
Total operating expenses for the fourth quarter of 2022 were $11.7 million compared with $22.2 million for the fourth quarter of 2021 and $16.4 million for the third quarter of 2022, a decrease of $10.5 million, or 47%, compared to the fourth quarter of 2021, and a decrease of $4.6 million, or 28.3%, compared to the third quarter of 2022.
Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the fourth quarter of 2022 were $10 million compared to $16.4 million for the fourth quarter of 2021, and $11.4 million for the third quarter of 2022.

DataGrail Leapfrogs Conventional Privacy Vendors, Unveils Modern Approach to Measuring and Understanding Risk

Retrieved on:

星期五, 三月 3, 2023

The Privacy Dashboard has received outstanding feedback from DataGrail customers, including Okta, Dexcom, Qualtrics, and Heartflow.

Key Points:

The Privacy Dashboard has received outstanding feedback from DataGrail customers, including Okta, Dexcom, Qualtrics, and Heartflow.
However, companies struggle to understand the impact of privacy risk as a leading indicator of overall business risk.
Key benefits of DataGrail’s Privacy Dashboard include:
Business risk reduction: DataGrail’s Privacy Dashboard grows with your business, offering the first privacy-specific interface to proactively reduce business risk.
Privacy ROI: Companies can communicate the value of automation across their privacy program to the rest of the organization.

Global Electronic Skin Patches Market Outlook Report 2022-2027: Remote Patient Monitoring Driving the Adoption of the Multi-billion Electronic Skin Patches Market - ResearchAndMarkets.com

Retrieved on:

星期二, 二月 28, 2023

Electronic skin patches are one of the latest waves in health monitoring; their non-intrusive design means they are comfortable and discrete.

Key Points:

Electronic skin patches are one of the latest waves in health monitoring; their non-intrusive design means they are comfortable and discrete.
The adoption of remote patient monitoring is increasing the use of electronic skin patches to transfer patient information directly to the healthcare provider or enter into the electronic medical records boosting the electronic skin patches market.
The global electronic skin patches market is likely to get highly dynamic with the presence of major international, regional, and a handful of local vendors offering electronic skin patches.
Abbott, Dexcom, General Electric Company, and Koninklijke Philips are vendors that contributed to a major share of the global electronic skin patches market.

Global Electronic Skin Patches Market Research Report 2022-2027: Emerging Trend of Digital Tattoos and Growing Number of Start-ups

Retrieved on:

星期一, 二月 27, 2023

DUBLIN, Feb. 27, 2023 /PRNewswire/ -- The "Electronic Skin Patches Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Feb. 27, 2023 /PRNewswire/ -- The "Electronic Skin Patches Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
These devices are being incorporated and connected to electronic skin patches, providing ease of use, and contributing to the growth of the global electronic skin patch market.
The global electronic skin patches market is likely to get highly dynamic with the presence of major international, regional, and a handful of local vendors offering electronic skin patches.
Latin America, the Middle East & Africa accounted for minimal shares in the global electronic skin patches market.

Dexcom Announces Upcoming Conference Presentations

Retrieved on:

星期四, 二月 23, 2023

Diabetes, Health Technology, Health, Medical Devices, Citigroup, Webcast, DXCM, Raymond, EST, Conference, Raymond James Financial, Dexcom, Cryptocurrency, Medtech

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:

Key Points:

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:
Sean Christensen, Vice President, Finance and Investor Relations, will present on behalf of the company at the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference on Wednesday, March 1, 2023 at 2:45pm (EST).
Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the Raymond James 44th Annual Institutional Investors Conference on Tuesday, March 7, 2023 at 3:25pm (EST).
Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

Dexcom G6 Continuous Glucose Monitoring System Launches in Singapore

Retrieved on:

星期三, 二月 22, 2023

Dexcom , Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of its Dexcom G6 CGM System in Singapore for people with diabetes ages two years and older, including pregnant women, and the appointment of DKSH Singapore Pte Ltd as sales, marketing, and distribution service provider.

Key Points:

Dexcom , Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of its Dexcom G6 CGM System in Singapore for people with diabetes ages two years and older, including pregnant women, and the appointment of DKSH Singapore Pte Ltd as sales, marketing, and distribution service provider.
"The launch of Dexcom G6 in Singapore is a significant milestone for our company," said Scott Moss, VP at Dexcom, Asia-Pacific.
Alternatively, patients can see glucose readings on the optional Dexcom G6 touch screen receiver that can be purchased separately.
Dexcom G6 CGM received its approval from Singapore’s HSA late last year and can now be accessed by Singaporeans this month.

Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally

Retrieved on:

星期三, 二月 22, 2023

“Last year at ATTD we first introduced our expanded portfolio of Dexcom CGM systems,” said Jake Leach, executive vice president and chief operating officer of Dexcom.

Key Points:

“Last year at ATTD we first introduced our expanded portfolio of Dexcom CGM systems,” said Jake Leach, executive vice president and chief operating officer of Dexcom.
From Spain to Estonia and the UK, more and more people living with diabetes are gaining access to real-time CGM as Dexcom ONE continues to launch in additional markets.
The company’s connectivity platform is helping make diabetes management more convenient than ever before for Dexcom G6 users.
Some of the most recent evidence showcasing the effectiveness of Dexcom CGM will be highlighted in posters, presentations and during the Dexcom Symposia at ATTD.

Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch

Retrieved on:

星期一, 二月 13, 2023

Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries.† Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17.

Key Points:

Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries.† Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17.
“When we set out to design G7, our goal was simple: to make the most accurate, easy-to-use CGM available for as many people with diabetes as possible,” said Kevin Sayer, chairman, president and CEO of Dexcom.
“The approval of Medicare coverage for G7 helps us deliver on that promise.
With Dexcom G7, the #1 recommended CGM brand8,9 now offers the most accurate1 and simple way to help people gain greater control of their diabetes.

Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on:

星期四, 二月 9, 2023

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022.

Key Points:

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022.
Fourth Quarter 2022 Financial Highlights:
Revenue grew 17% versus the same quarter of the prior year to $815.2 million on a reported basis and 20% on an organic1 basis.
Operating Income: GAAP operating income for the fourth quarter of 2022 was $125.4 million, compared to GAAP operating income of $0.6 million for the fourth quarter of 2021.
Non-GAAP operating income* for the fourth quarter of 2022 was $172.1 million, compared to non-GAAP operating income of $11.9 million for the fourth quarter of 2021.